Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › erenumab

erenumab

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of erenumab

25 trials tracked of erenumab: 12 in phase 3 or 4 and 10 with published results. The most-cited published study has 179 citations.

25Trials tracked
12Phase 3 & 4
0Recruiting
10With published results
Phase distribution
Phase 4 7 Phase 3 5 Phase 2 6 Phase 1 7
  1. Phase 4 Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic and Chronic Migraine Completed · 179 cited
  2. Phase 3 Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention Completed · 96 cited
  3. Phase 3 Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine Patients Completed · 65 cited
  4. Phase 3 Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention Completed · 41 cited
  5. Phase 4 Imaging the Migraine Brain Pre- and Post-Erenumab Completed · 32 cited
  6. Phase 3 Study of Efficacy and Safety of Erenumab in Adult Chronic Migraine Patients Completed · 32 cited
Show 19 more trials
  1. Phase 3 A Controlled Trial of Erenumab in Migraine Prevention Completed · 22 cited
  2. Phase 4 Biomarker and Genetic Predictors of Erenumab Treatment Response Completed · 16 cited
  3. Phase 4 Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study Completed · 4 cited
  4. Phase 4 Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine Completed
  5. Phase 4 A Study of Gastrointestinal Emptying Time in Adult Participants With Migraine Before and After Start of a mAb CGRP Antagonist Completed
  6. Phase 4 A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine Completed
  7. Phase 2 A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention Completed
  8. Phase 2 Treadmill Cardiovascular Safety Study of Erenumab (AMG 334) Completed
  9. Phase 2 Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention Completed
  10. Phase 2 A Study to Assess the Long-term Safety and Efficacy of Erenumab (AMG 334) in Chronic Migraine Prevention. Completed
  11. Phase 2 A Safety and Efficacy Study to Evaluate AMG 334 in Migraine Prevention Completed
  12. Phase 2 Multidisciplinary Translational Approach to Investigate Mechanisms Predictors & Prevention of Persistent PTH Completed
  13. Phase 1 Ascending Multiple-Doses of Erenumab (AMG 334) in Healthy Adults and in Migraine Patients Completed
  14. Phase 1 Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine Completed
  15. Phase 1 Study of Erenumab (AMG 334) in Women With Hot Flashes Completed
  16. Phase 1 To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients Completed
  17. Phase 1 Study to Evaluate the Effect of Erenumab on Blood Pressure When Given Concomitantly With Subcutaneous Sumatriptan Completed
  18. Phase 1 Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy Females Completed
  19. Phase 1 Ascending Single Doses of Erenumab (AMG 334) in Healthy Adults and Migraine Patients Completed

Showing the 25 most-cited and recently-updated of 25 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
30% of pediatric patients with migraine report at least one adverse event during pharmacological prophylaxis
Pediatrics Meta-analysis
30% of pediatric patients with migraine report at least one adverse event during pharmacological prophylaxis Trial Shows Specific Side Effects for Children with Migraine
This meta-analysis of 2742 patients evaluates the safety profile of various pharmacological migraine prophylaxis treatments in children and …
About 30% of children and adolescents taking migraine prevention medication report experiencing at least one side effect during treatment.
Jul 8, 2026
Bayesian network meta-analysis compares CGRP therapies for episodic migraine
Neurology Meta-analysis
Bayesian network meta-analysis compares CGRP therapies for episodic migraine New migraine drugs show big benefits over placebo for monthly attack counts
This Bayesian network meta-analysis synthesized evidence on six CGRP-targeted therapies for episodic migraine. It found that monoclonal anti…
New migraine drugs cut monthly attacks more than placebo, with injectables slightly better than pills for some people.
medRxiv May 25, 2026